|View printer-friendly version|
|June 28, 2018 8:00 a.m.|
|Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific Meeting|
One late breaker, three platform presentations and 23 posters showcase fremanezumab as an investigational treatment for the prevention of migraine
“Migraine remains a challenging disease with considerable unmet need,
due to availability of few therapeutic innovations over the past 25
Antibodies targeting calcitonin gene-related peptides (anti-CGRPs), such as fremanezumab, are a new class of therapies developed for the prevention of migraine in adults.
Teva-sponsored abstracts at the AHS Annual Scientific Meeting include:
Late-Breaking Poster Presentation:
Long-Term Impact of Fremanezumab Posters (
Fremanezumab is an investigational therapy currently under review by the
Fremanezumab is a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand, currently being investigated as a preventive treatment for migraine. With limited availability of preventive treatment options, fremanezumab represents a potential new option to address a significant unmet medical need.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Fremanezumab, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the
Teva Pharmaceutical Industries Ltd.